-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Early intervention in rituximab, a drug used to treat rheumatoid arthritis (RA), can reduce the risk of
"Patients with new-onset myasthenia who received Merohua as a supplement to standard of care showed greater improvement compared to patients taking a placebo," said
In myasthenia gravis, the immune system attacks receptors between nerves and muscles, leading to abnormal muscle weakness and fatigue
There is only one approved drug for the treatment of muscle weakness, Soliris, but the treatment is expensive, which means that very few patients – who have so far not had patients in Sweden – benefit
The current study included 47 adult patients who had been diagnosed with muscle weakness
Four months later, according to a well-established scale of 13 scores, 71 percent of the rituximab group had the disease well controlled, compared to 29 percent
The Merohua group also received a lower dose of cortisone on average and required fewer
The researchers note that the study was relatively small in scale and that there was an imbalance in some baseline features between the two groups, which is a limitation
Fredrik Piehl said: "Even before the results of the study were finalized, the number of people using Merovar for muscle weakness in Sweden increased
The study was funded
Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial
